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The Asian Prostate Cancer (A-CaP) study is an Asia-wide initiative that was launched in December 2015
in Tokyo, Japan, with the objective of surveying information about patients who have received a his-
topathological diagnosis of prostate cancer (PCa) and are undergoing treatment and clarifying distri-
bution of staging, the actual status of treatment choices, and treatment outcomes. The study aims to
clarify the clinical situation for PCa in Asia and use the outcomes for the purposes of international
comparison. Following the first meeting in Tokyo in December 2015, the second A-CaP meeting was
held in Seoul, Korea, in September 2016. This, the third A-CaP meeting, was held on October 14, 2017, investigation on Comprehensive Cancer Network, Graduate School of Interdisciplinary Information Studies, University of
apan.
te Society, Published by Elsevier Korea LLC. This is an open access article under the CC BY-NC-ND license (http://
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RegistryChiang Mai, Thailand, with the participation of members and collaborators from 12 countries and re-
gions. In the meeting, participating countries and regions presented the current status of data collec-
tion, and the A-CaP office presented a preliminary analysis of the registered cases received from each
country and region. Participants discussed ongoing challenges relating to data input and collection,
institutional, and legislative issues that may present barriers to data sharing, and the outlook for further
patient registrations through to the end of the registration period in December 2018. In addition to A-
CaPespecific discussions, a series of special lectures were also delivered on the situation for health
insurance in the United States, the correlation between insurance coverage and PCa outcomes, and the
outlook for robotic surgery in the Asia-Pacific region. Members also confirmed the principles of
authorship in collaborative studies, with a view to publishing original articles based on A-CaP data in
the future.
© 2018 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The third meeting of the Asian Prostate Cancer (A-CaP) study
was held on October 14, 2017, in Chiang Mai, Thailand, in
conjunctionwith the seventh Congress of the Asian Pacific Prostate
Society 2017. The meeting was attended by representatives of 10
countries and regions in Asia participating in the study (China,
Hong Kong, Indonesia, Japan, Korea, Malaysia, Philippines,
Singapore, Thailand, and Turkey) and collaborators from the United
States and Australia. Following on from the A-CaP launch sympo-
sium in December 20151 and the second A-CaP meeting in Seoul,
Korea, in September 20162, members discussed the current status
of progress with patient registration, the outlook for further
registrations and ways inwhich to utilize the database that is being
accumulated through the A-CaP project. In the business meeting
held before the scientific meeting, the A-CaP office also proposed
the distribution of a tuned-up Excel-based input system for those
countries that are collecting data in Excel-based format, as a
measure to help ensure data consistency and minimize time
required for data cleaning. Special lectures were provided by col-
laborators from the United States and Australia. The following is a
summary of the proceedings of the symposium.
2. Year report from each A-CaP member country: part I
2.1. Japan
Mizuki Onozawa (Tokyo-Kita Medical Center) noted that patient
registration started in July 2016 and the number of registered pa-
tients is increasing gradually. As of October 13, 2017, there are 6,300
patients registered, although this presentation would be based on
5,275 patients and compare data with previous database studies in
Japan.
The median patient age is about 70 years, and there is no clear
difference between studies. About 10% of patients have metastatic
disease. In terms of PSA distribution, there was no remarkable
difference between jpA-CaP2016 and J-CaP2010 data.
In terms of first linemain treatment, the proportion of hormonal
therapy is rapidly decreasing. In the JUA2000 data, more than half
were treatedwith hormonal therapy; whereas, in jpA-CaP2016, this
proportion had fallen to 34.0%.
In terms of radical prostatectomy, the proportion of robot-
assisted prostatectomies has increased drastically since J-CaP2010
data. This is because robot-assisted surgery is now approved under
the Japanese health insurance system.
The number of newly registered patients is steadily
increasing. As of July 2017, there seems to be no remarkable
differences in patient and tumor background factors during thepast several years. However, clinical practice patterns are
dramatically changing in Japan.
2.1.1. Discussion
Matthew Cooperberg (UCSF) asked about trends in screening.
Mizuki Onozawa responded that screening is gradually spreading
in Japan. Screened patients account for only a small proportion of
newly diagnosed patients.
Levent Türkeri (AcıbademUniversity) asked why 35% of patients
still received only hormonal therapy. The main reason is that Jap-
anese patients like to be treated conservatively and prefer to
receive some kind of treatment, even for localized cancer. Hideyuki
Akaza (University of Tokyo) noted that many Asian people choose
hormonal therapy, even when cancer is localized. However, the
proportion of hormonal treatment is gradually decreasing.
Kim Moretti (University of South Australia) noted that active
surveillance has not increased a great deal and asked why the
reason for the low rate of active surveillance is because patients
prefer to have some kind of treatment.
Yoshihiko Hirao (Osaka Gyoumeikan Hospital) noted that Japa-
nese people can receive the treatment they want, but only very low
risk patients are accepting of active surveillance.
Mikio Namiki noted that patients that would normally be
receiving active surveillance in the United States and elsewhere are
generally receiving hormonal therapy in Japan.
2.2. Korea
Seung Hwan Lee (Yonsei University, Korea) noted that according
to the trend of prostate cancer (PCa) incidence in Korea, about
10,000 people were newly diagnosed in 2014. The PCa survival rate
was about 93.3% for the period 2011e2015, thanks to the effect of
widespread use of PSA and early detection programs. In Korea,
newly diagnosed PCa cases in 2016 amounted to 6,291 cases, and
approximately 3,000 cases will be used for the purposes of A-CaP
data.
2.2.1. Discussion
Zhu Gang (Beijing United Family Hospital and Clinics) asked
about active surveillance in Korea. Seung Hwan Lee responded that
in Korea it is the situation that many people who are diagnosed
with cancer want to receive some kind of treatment. Therefore,
active surveillance is not a popular option.
Zhu Gang noted that active surveillance is also very low in Japan
and also China. It seems to be the philosophy of Asian people to
seek to receive treatment that will help them to be rid of disease.
Hideyuki Akaza asked about the situation in Turkey. Levent
Türkeri responded that the Turkish health-care system is based on
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appealing to physicians. The Urooncological Society of Turkey is
working to convince doctors that active surveillance should be a
part of their treatment strategy. However, the rate is still very low. It
is to be hoped that in the future the amount of active surveillance
will rise.
Kim Moretti noted that active surveillance accounts for about
25% in South Australia. However, in the A-CaP database, this is only
15%. He suggested that it may be useful to look at the A-CaP data in
this regard. He noted that active surveillance is sold in Australia as a
way of avoiding nasty side-effects.
Matthew Cooperberg noted that the situation used to be the
same in the United States, namely that doctors sought to treat low-
risk disease. In a couple of years, however, after changing treatment
guidelines, the active surveillance rate rose from 10% to 40%. It is
important to educate the patients that cancer is not all the same
and that active surveillance may be preferable.
Shigeo Horie (Juntendo University Graduate School of Medicine)
noted that it is important to stress the difference between PCa in
Asian and Caucasian populations.
Matthew Cooperberg noted that the question of low-risk dis-
ease management has been important in the West. Twenty-five
percent of patients on active surveillance experience cancer pro-
gression, whereas 75% do not. There needs to be a better system for
considering active surveillance.
2.3. China
Zhu Gang noted that PCa is the sixth most prevalent cancer
among male cancers. PCa has been increasing over the years and
mortality is also increasing. Five-year survival for PCa is 53.8% in
China compared to 100% for the United States. The Chinese PCa
database is awell-designed, ready-for-use database, and over 5,000
cases have been registered, although they are pending at the cur-
rent moment. Data for 499 cases have been transferred to A-CaP,
from hospitals around China. C-CaP is a collaborative body with A-
CaP. In China the overwhelming majority of A-CaP patients have
been treated with prostatectomy. So far, in 2017, 52 cases have been
collected for A-CaP purposes.
2.3.1. Discussion
Rainy Umbas (University of Indonesia) asked about the clinical
practice in examining PSA and asked if there are any PSA training
programs for urologists. Zhu Gang responded that there is no na-
tional screening program in China, but at his hospital, a screening
program has been introduced for the six most prevalent cancers in
China.
Bannakij Lojanapiwat asked about modalities for staging, noting
that not many people seem to have computed tomography (CT) or
magnetic resonance imaging (MRI) scans. Zhu Gang noted that it is
usually the case that patients have an MRI scan before having a
biopsy.
2.4. Malaysia
Teng Aik Ong (University of Malaya) noted that the Malaysian
National Cancer Registry Report 2016 covers the 5-year period from
2007e2011. For males, PCa is the third most common cancer. On
average, there are approximately 600 new cases a year.
In terms of the PCa cases in all participating centers (n ¼ 5), the
total number of new cases recruited in 2016 amounted to 371. In
terms of ethnic profile, Malays and Chinese account for the ma-
jority. For the Malay population, the average age at presentation is
68.8 years, which is lower than the Chinese ethnic population, and
the Malay population have a median PSA of 58.8 ng/ml atpresentation, which is higher than Chinese (25.0 ng/mL) and Indian
(31.0 ng/mL) ethnicities.
Modalities for staging include bone scan (50%), MRI (29%), and
CT (20%).
In Malaysia active surveillance accounts for 10.8% of primary
treatment cases, with ADT þ chemotherapy accounting for 48.9% of
primary treatment depending on the stages of the disease. The
majority of cases (53.4%) present with Stage IV cancer at diagnosis.
Common comorbidities include hypertension, hyperlipidemia, and
diabetes.
The budget from A-CaP (38,145 RM) has been used for the study,
in addition to which a grant from NIH Malaysia was also received
(50,780 RM). Efforts will continue in 2017.
2.4.1. Discussion
Jasmine Lim (University of Malaya) suggested that it would be
useful to prepare a concept form for utilizing the data from the A-
CaP database.
Ji Youl Lee (The Catholic University of Korea) noted that the fact
that grant money had been procured from NIH Malaysia was a very
good example.
Jun Miyazaki (International University of Health and Welfare)
asked about screening in Malaysia. Teng Aik Ong responded that
there is no screening program in Malaysia.
Jason Letran (Cardinal Santos Medical Center) asked if there is
any correlation between outcomes and diagnosis and the patient's
financial means. Jasmine Lim noted that perhaps one of the reasons
why Malay present later is due to an issue of awareness. During
health awareness campaigns, it is generally ethnic Chinese who
attend clinics.
Yoshihiko Hirao asked about the number of urologists in
Malaysia. Teng Aik Ong responded that there are 111 urologists,
which is a low number.
2.5. Indonesia
Lukman Hakim (Airlangga University) reported that the A-CaP
study in Indonesia started in April 2016, with a meeting in Jakarta
involving eight teaching hospitals. A board of advisors was
appointed, and a simple web-based application system was
announced, which was changed to MS Access. Enrollment started
on April 1, 2016.
Currently there are nine hospitals participating, and a total of
189 new patients have been registered between April 2016 and
October 12, 2017. A dictionary has been distributed to enable doc-
tors to fill in the input system. In terms of themodalities for staging,
CT and MRI were only used if imaging would change the definitive
treatment. Despite the fact that bone scans were rarely used due to
limited facilities particularly in the peripheral hospitals, bone sur-
vey was performed in the majority of cases.
In terms of initial PSA, the majority of patients have a PSA in
excess of 20.
In terms of initial treatment, ADT without chemotherapy with
radiotherapy is the predominant therapy (55%).
In terms of constraints, there is a risk of patients being lost in
follow-up. There is also a difference in diagnostic facilities between
hospitals. Another challenge is inconsistency in the standardized
pathological reports between hospitals. There are differences of
perception between study coordinators in under the study proto-
col. The “transition period” of the newly launched Indonesia Uni-
versity Health Coverage system is also presenting constraints as
there are maximum budgetary limitations being imposed.
In terms of next plans, the hope is to involve more satellite
hospitals and launch aweb-based application very soon, which will
help to facilitate data submission. Aworkshop is also being planned
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standardized reporting of specimens. It is also important to
emphasize the study protocol among principle investigators.
2.5.1. Discussion
Hideyuki Akaza referred to the transition period to University
Health Coverage in Indonesia. He asked how many patients do not
come to hospital for treatment. Lukman Hakim responded that a
population-based survey in Indonesia reported that 35% of sick
people go to a traditional healer in the first case to seek cure. In
terms of transportation and financial background, there are some
regional areas that make it difficult for some patients to visit hos-
pital. The ministry of health is considering the implementation of
financial support for transportation to hospital, but it is still not
known when it will be implemented.
Hideyuki Akaza asked about medical and surgical castration and
which one the patients choose. Lukman Hakim noted that due to
the asymmetrical health information, it is usually the urologists
who decide for patients. It is generally the case that surgical
castration is practiced for patients who live in rural areas. If it is felt
that the patient can be followed up regularly, medical castration is
used.
2.6. Hong Kong
Ng Chi Fai (The Chinese University of Hong Kong) noted that
data are being collected by three out of nine hospitals in Hong
Kong, which covers more than 40% of the population. Ethical
approval was received more than 2 years ago, and the hospitals are
collecting data from Tuen Mun Hospital & North District Hospital,
which regularly compiles lists of newly diagnosed cases. The Prince
of Wales Hospital assists in data entry. In Hong Kong, there is a very
good electronic hospital record system (Clinical Management Sys-
tem) for collecting data and other elements that are required for
utilization in the A-CaP study.
In terms of current progress, a total of 295 cases have been
collected in 2016.
In terms of major challenges, the cases collected from Hong
Kong are from a public hospital system and there is delayed
availability of data, including imaging, final plans and operation
results, etc.
2.6.1. Discussion
Teng Aik Ong asked about the percentage of patients who are
metastatic. Ng Chi Fai responded that about 25% are metastatic.
Jason Letran asked about waiting times for imaging and surgery.
Ng Chi Fai responded that that the hospital system is public, and
there can be considerable waiting times, up to a few months.
2.7. Turkey
Levent Türkeri noted that the Turkish database was already
established ahead of the A-CaP study. This has created some
problems because the Excel tables needed to be converted, which
required manpower to create the necessary files.
In Turkey, the T category has changed in recent years, and the
majority is localized disease, with only approximately 15% pre-
senting with metastatic disease. This is thanks to PSA screening.
In terms of modalities for staging, PET scanning has started to be
used, and it is also proving to be expensive.
In terms of information on initial treatment of patients in the
Turkish database, 84.4% received treatment for local treatment. In
95% of cases of local treatment, the treatment was radical prosta-
tectomy. A very small number received radiotherapy, hormonal
therapy, or active surveillance.In terms of the types of radical prostatectomy, open radical
prostatectomy (ORP) is 57.5% and robot-assisted radical prostatec-
tomy (RARP) is 41.6%, and the proportion of RARP is likely to in-
crease in the future.
In terms of treatment for metastatic disease, the most used
treatments are LHRH þ flare protection and CAB. AA monotherapy
is used in approximately 17% of cases.
The Urooncological Society of Turkey database has been sub-
jected to a renovation. A meeting was held for quality control, and
dedicated data managers have been hired to work for the society in
Istanbul, Ankara, Izmir, and Adana.
As of September 2017, there are now 1,838 patients in the
database, and it is expected that this number will increase to 3,000
patients by the end of 2018, thanks to the hiring of the dedicated
data managers.
2.7.1. Discussion
Yoshihiko Hirao asked whether patients are from metropolitan
areas or rural areas. Levent Türkeri responded that the majority of
cases are from urban areas, as the majority of the population now
lives in urban areas. The main information will be coming from
cities, including public or teaching hospitals.
Bannakij Lojanapiwat noted that Turkey covers two continents
and asked about the ethnicity of patients. Levent Türkeri responded
that the population of Istanbul is 20 million, and one in four of the
population of Turkey live in the city, and this population reflects the
general population.
2.8. Thailand
Bannakij Lojanapiwat reported that 264 patients have been
registered so far for the A-CaP study from three hospitals, one of
which is in Chiang Mai. In the case of Chiang Mai, the PSA level on
presentation is very high compared to the case of Bangkok, which
reflects the lag in terms of screening in the Chiang Mai region. The
staging of cancer is also higher in Chiang Mai, and metastatic dis-
ease is higher than in Bangkok.
In terms of initial treatment, in Chiang Mai, the majority of cases
are treated with ADT as main treatment, and there is also a higher
incidence of active surveillance, whereas hospitals in Bangkok offer
more cases of radical prostatectomy.
2.8.1. Discussion
Hideyuki Akaza noted that Chiang Mai could provide a good
model for treatment in rural areas. Bannakij Lojanapiwat noted that
in urban areas patients live in closer proximity to hospitals, which
makes it easier for patients to visit hospital. The situation in Chiang
Mai reflects the situation in regional areas.
2.9. Singapore
Edmund Chiong (National University Health System) reported
that the population of Singapore is 5.3 million, and PCa is the third
most common cancer in Singaporemen. It is the sixth leading cause
of cancer death. When it comes to the national cancer registry, 30%
of people present with Stage 4 cancer.
With regard to the S-CaP study, the three participating hospitals
in the cluster system maintain their PCa databases in individual
hospitals and academic institutions. However, there have been
various regulatory changes to the system in Singapore in the past
year. It is hoped that the clustering system that has been estab-
lished this year will help in the collection of data.
In terms of progress, the official platform for data collection is
REDCap, which will help to harmonize data fields and central
subject identification. All hospitals have REDCap training. Single
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patient have been completed, and informed consent has also been
gained. Each hospital retains its own database autonomy, and data
sharing agreement contracts are required between hospitals, which
is why data have not yet been shared with A-CaP.
A multisite IRB was approved in August 2017. Two sites have
already been initiated, with a third site making preparations. All
patients have been histologically diagnosed with PCa from January
1, 2016 onwards. Informed consent has been obtained from all
patients. Thus far data for 71 patients have been registered.
The median age is 69 years, and the median PSA was 13.8 mg/L,
and specimens are largely taken by biopsy. In terms of stage dis-
tribution, most patients are T1 and T2. The use of CT scans is fairly
common, and MRI is also increasing. Bone scanning is not generally
implemented for low-risk disease.
In terms of initial treatment, the most used is ADT ± chemo-
therapy, followed by active surveillance/ watchful waiting
(AS/WW) and prostatectomy.
The major challenge is the passage of the Human Biomedical
Research Act, which is a complex piece of legislation that will have a
significant impact on the way human biomedical research is con-
ducted. Specific issues include the requirement for informed
consent and implications for data-sharing agreements.
The challenges that need to be resolved are the funding of
research assistants, accurate follow-up data and oversights, the
time needed for contractual agreements between institutions and
with A-Cap on data-sharing, and participation of other institutions,
which is still pending due to resource limitations.
2.9.1. Discussion
Shiro Hinotsu noted that using the REDCap system each insti-
tution must have a server and a mainframe. He asked whether each
hospital maintains its own server and mainframe. Edmund Chiong
responded that all hospitals in Singapore are now electronic, but
unfortunately, they all use different systems. The new law also
stipulates that each hospital is in its own legal entity, which is why
contracts need to be concluded.
YoshiyukiHirao referred to IRB andaskedwhetherA-CaPwasopt-
out or opt-in. Edmund Chiong responded that in Singapore, the sys-
tem ismore likeanopt-in, in that it is compulsory toacquire informed
consent from patients to share their data with A-CaP. The consent
form for informed consent will be the same for all institutions.
2.10. Philippines
Jason Letran reported that the Philippines had collected a total
of 197 patients in 2016 and a total of 43 in 2017. For the patients
who report their age, the average age is in excess of 65 years. Most
patients have a college education and are from urban areas. With
regard to initial PSA levels, 61.3% patients have a level less than 20.
Forty percent of patients are T3; 21.7% of patients received a CT
scan and 22.9% received an MRI scan. A bone scan for staging was
performed on 57.9% of patients.
In terms of initial treatment, 25.8% received RP, 17.9% received
radiotherapy, and 8.75% received ADT. Active surveillance accounts
for only 1.25% of initial treatment. Treatment was not specified for
41.3% of patients.
In terms of active surveillance, I would like to present a com-
parison between our data and that of a study in Toronto. The me-
dian PSA of active surveillance patients in the Philippines is
13.9 compared to 6.2 in Canada. 115 of 168 patients had clinical T1
upstaged to T3.
I think that more than cultural differences with regard to active
surveillance, these results show scientific differences, and this is
where the importance of the Asian focus of A-CaP comes to the fore.I would like to propose a joint study as a means of supporting the
relative lesser usage of active surveillance. We hope to contribute
more patients to the study in the future.
2.10.1. Discussion
Bannakij Lojanapiwat noted that many items of data are missing
from Philippine patients, and this is a problem that was also
encountered in Thailand. He suggested thatmore efforts bemade to
explain the kind of data that are needed.
Hideyuki Akaza noted that Jason Letran had made a very
important proposal about the comparison of Asian and Western
patients who undergo active surveillance and the need to check
histological differences among patients. He noted that he would
like to consider the possibility of engaging in such a study.
Yoshiyuki Hirao noted that the in Philippines there are many
islands, and perhaps the 371 urologists are living in urban areas. He
asked about the situation for rural areas. Jason Letran responded
that half the urologists are located in metro Manila, serving only
15% of the population. With regard to screening campaigns, he
noted that on the Saturday before Fathers' Day, a campaign is also
implemented to raise awareness about PCa.
3. Special lectures: toward realization of universal health
coverage for prostate cancer treatment
3.1. US health care: the current controversy
Matthew Cooperberg noted that the US healthcare system is
costly because of high premiums and a high co-pay structure, but
this does not necessarily translate to better care. The United States
spends more than twice on health-care than other industrial na-
tions, but this is not reflected in life expectancy. One of the reasons
for this is inequality.
For PCa, the total cost of care was US$12 billion in 2010. Lifetime
costs exceed US$110,520 per patient. 62% are insured by
Medicare and 32% by commercial or private payers. There are also
an increasing number of patients receiving more than one treat-
ment. The costs are increasing due to new therapy and use of
multiple therapies.
Something needed to be done to address the health-care system
in order to make sure that all Americans are able to get health in-
surance. The Patient Protection and Affordable Care Act (ACA) or
“Obamacare”was signed into law on 2010. ACA requires individuals
who do not receive health insurance benefits through their em-
ployees to purchase coverage or pay a penalty. It puts certain limits
on what insurers may or may not do with respect to eligibility and
coverage. One disadvantage was that ACA was not formulated in
consultation with doctors.
The key provisions of ACA are dependents may be covered by
their parents' insurance plans until they turn 26; insurers may not
cancel polices when policy holders become sick; state health in-
surance exchanges allow businesses and individuals to compare
plans and enroll for coverage; insurers may not place a lifetime
monetary limit on hospital stays or other benefits deemed
“essential” in new policies; and insurers may not deny coverage to
individuals for preexisting conditions.
ACA also imposes an individual mandate, requiring all in-
dividuals to carry insurance or pay a tax penalty. Subsidies will help
low-income people comply with this mandate. Larger employers
will be charged a US$2,000 penalty per full-time employee who
lacks health coverage.
Insurers are required to provide individuals with a standardized,
plain-language summary of benefits and any rate increases of more
than 10%must be publicly justified. Certain types of preventive care
must be covered at no additional cost to the patient, and patients
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ment for health-care services.
The most controversial components are the requirement that
nearly every individual in the United States have health-care
coverage. Young, relatively healthy people who pay regular insur-
ance premiums ultimately help cover the costs of older and less-
healthy individuals. Since insurance companies may not refuse to
cover those with preexisting conditions, the mandate will
discourage people from simply waiting until they have a health-
care emergency.
The primary mission of ACA was to get more insurance for
Americans, and it was quite successful, cutting the rate of unin-
sured people by half and ensuring better access to care as a result.
Now the biggest excuse for not receiving care is that people do not
have a primary care physician.
The negative aspects of ACA are that many businesses have
found it cheaper to pay the penalty rather than pay for insurance
policies for their employees and that insurance companies have
canceled some plans that did not cover essential benefits.
In addition, in terms of medical expense deductions, the level
increased to 10% from 7.5% of income. Another issue is that ACA
does not address out of pocket expenses for prescription drugs.
The public perception of health care is that ACA may not have
much of an impact beyond those covered by Medicaid expansion
and the marketplace. Thirty-one percent of Americans aged 18e64
years report they or a family member face problems paying health-
care bills. Out of pocket costs are also increasing, and the average
deductible for employee-provided health-care coverage rose from
$303 to $1,505 between 2006 and 2007.
With regard to ACA and cancer care, there are subsidies for those
with low incomes. People cannot be denied coverage or dropped
from coverage because of having cancer. There are concerns that
narrow networks are being formed to control costs and limit access,
and cancer centers are being excluded from private networks.
Although ACA does not address all issues in the US health-care
system, the proposal by the Trump administration to repeal the
ACA failed, suggesting that it has broad overall support. There are
current moves toward amending ACA, and there is a possibility that
any revisions could negatively impact cancer care3.
3.1.1. Discussion
Levent Türkeri noted that he would like to learn about the
opinion of urologists with regard to the ACA. Matthew Cooperberg
responded that hospitals have done a very good job of pitting pri-
mary care doctors against specialists. If you look at academic
medical centers, academics are very much in favor of ACA. Physi-
cians have been very shortsighted, and because they do not work as
a group, they have not had a place at the negotiating table to
formulate the ACA.
Hideyuki Akaza noted that the Japanese insurance system is
very different to the ACA and is available to all people. There is no
private insurance system in Japan for cancer care.
3.2. Insurance and prostate cancer outcomes: a perspective from
the US health-care “System”
Matthew Cooperberg noted that the US health-care system is
highly fragmented, including private, public, employer-based, and
Medicare for people aged above 65 years. There are no centralized
data covering all populations, and patients with no insurance do
not make it into most databases. Insurance prices are opaque, and
consumers bear a variable portion of the cost. Centers of excellence
tend to treat patients with the best and the worst insurance. The
ACA really only tried to resolve coverage issues, rather than quality
and cost issues.Individual costs for US citizens include their share of the pre-
mium, deductibles, and co-pay portions. The federal system will
pay for people aged above 65 years (Medicare), people on low in-
comes (Medicaid), veterans (Veterans Affairs), and through the
Indian Health Service. In terms of private insurance policies, med-
ical loss ratios sustained by insurance companies have improved
since the ACA, but the question remains as to whether quality is
better. For-profit insurance costs more, but does not necessarily
provide the best health care.
In terms of insurance distribution in CaPSURE, those persons
without insurance were basically not able to register in the CaP-
SURE database. In the CaPSURE database, overall approximately
15% of patients had only Medicare insurance, while 35% had
Medicare with extra insurance. Forty-two percent of patients had
private insurance, and 3% had Veterans Affairs insurance.
With regard to the question of whether insurance affects
outcomes, in a univariate analysis of insurance and prostate
cancer specific mortality (PCSM), there are some differences.
Patients with private insurance rather than Medicare (Ref value
1.0) had an approximately 50% reduction in mortality (0.55),
whereas those patients with no insurance had an increased
mortality rate (1.75).
However, in figures adjusted for age that compare insurance and
PCSM, the difference between patients on Medicare (1.0) and those
with private insurance (0.93) decreases, although the PCSM for
those with no insurance is still higher (2.68).
In figures adjusted for age and SES, the difference between
Medicare (1.0) and private insurance (0.95) remains small, but the
PCSM for those without insurance remains high (2.10), although
less than the model adjusted only for age.
However, in figures adjusted for age, with SES and risk, insur-
ance is no longer predictive: Medicare (1.0), private insurance
(0.82), and no insurance (1.35). The only aspect that is predictive is
risk, meaning that if you have no insurance you tend to have higher
risk of disease at presentation.
In figures adjusted for age, SES, risk and treatment type, and the
type of insurance become even less predictive: Medicare (1.0),
private insurance (0.79), and no insurance (1.20).
Regarding question of whether treatment variation explains
disparity in insurance coverage, although patients with private
insurance are more likely to get surgery, treatment is more driven
by age than anything else. Broken down by age category, there is
very little difference. A previous CaPSURE study showed that there
can be regional differences in the choice of treatment, but this is not
related to insurance coverage.
The Surveillance, Epidemiology, and End Results (SEER) Pro-
gram has some data, but it does not have a great deal of granularity,
lacking data about risk. It is, however, one of the greatest sources of
information about uninsured patients. It shows that uninsured
patients tend to present with high-risk disease (30.7%) rather than
insured patients (21.1%). The likelihood of metastatic disease is also
greater in uninsured patients (11.9%) than insured patients (2.6%).
Insurance therefore can be said to drive outcomes in terms of
screening and early diagnosis. In a multivariable analysis of the
SEER data, the likelihood of metastatic disease is five times greater
in uninsured patients at time of diagnosis than insured patients.
The likelihood of being treated for high-risk non-metastatic disease
is two-fold higher in insured patients. The SEER data also show a
40% survival advantage for patients with insurance, but data on risk
is not comprehensive. The AQUA registry is expected to comple-
ment SEER data in the future. 60,000 patients from the first 100
practices have been registered on AQUA since 2014, and this reg-
istry provides much richer data than SEER. However, until more
“safety-net” hospitals join, capturing data on uninsured patients
will remain challenging.
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disentangle from other sociodemographic factors, including race,
diet, lifestyle, and access to care. A lack of insurance predicts not
only delayed diagnosis and undertreatment but also less over-
treatment. A previous CaPSURE study has shown that PCa might be
the first condition in the US where rich white men got worse care
because they were more likely to be overtreated for low-risk dis-
ease. The effects of underinsurance are more difficult to discern.
The US health-care system is a mess and unlikely to be fixed in the
near future without political campaign finance reform and more
influence by physicians3.
3.2.1. Discussion
Hideyuki Akaza noted that the results of the data presented
suggest that there is little difference in outcomes. Matthew Coop-
erberg noted that for low income men, their outcomes are okay if
they make it into the system, but the question is whether they can
actually make their way into the system in the first place.
Shiro Hinotsu asked whether patient payment data are recorded
on the CaPSURE or SEER databases. Matthew Cooperberg respon-
ded that there are no data, as onlyMedicare tracks what it pays, but
there is no tracking of self-pay components.
3.3. From robotic surgery to CRPC: How do we demonstrate value in
the Asia-Pacific region?
Declan Murphy (Peter MacCallum Cancer Centre) noted that he
would be assessing the value of robotic surgery in a public hospital
setting and discuss a precision approach in metastatic PCa.
Compared to other countries, the United States spends more
than double on health care as a percentage of GDP. This suggests
that there needs to be massive reform in the US Robotic surgery, is
an example of an expensive intervention that is impacting the
Asia-Pacific region. In a article published year titled, “Patterns-of-
care and health economic analysis of robot-assisted radical pros-
tatectomy in the Australian public health system,” it has been
shown that RARP performs better than ORP, but there is higher
cost due to longer operating times. Once the number of cases
reaches a certain level at a medical institution, the costs will,
however, decrease.
In this study, the aim was to evaluate RARP in a public health
system, comparing outcomes to current standards and conduct a
health-economic analysis within an activity-based funding system.
The results showed that patients had a shorter stay in hospital
(1.4 days) for RARP than ORP (4.8 days). Length of stay was there-
fore greatly reduced through RARP. Positive surgical margins
(PSMs) showed that patients undergoing RARP are significantly less
likely to have a PSM compared with open or laparoscopic RP. Pa-
tients with a PSM are five times more likely to receive additional
treatment within 12 months.
In a health-economic analysis, it was shown that RARP reduces
hospital stay, blood transfusion rates, and positive surgical margins.
However, it is expensive. If high-volume, high-quality cases are
performed, it makes RARP cost-effective.
How are we going to make CRPC drugs more affordable in Asia?
The question is whether it is possible to convince big pharma to
dramatically increase access in the Asia-Pacific region. The answer
to this question is “very unlikely.” Different strategies will be
required to make drugs more affordable. For example, primary
resistance to AR-targeted agents can be detected early, and this
would help to reduce the use of androgen receptor (AR)-targeted
agents.
Integrative landscape analysis of somatic and germline aber-
rations in mCRPC shows that 90% of mCRPC harbor clinically
actionable molecular alterations, and 23% of mCRPC harbor DNArepair pathway aberrations. An editorial in European Urology
titled, “The Evolving Narrative of DNA Repair Gene Defects: Dis-
tinguishing Indolent from Lethal Prostate Cancer,” makes four
points, namely that DRG mutations, most notably BRCA2, are
enriched in mCRPC, which are present in the germline or in so-
matic tumors in up to one in four patients. Secondly, these DRG
aberrations are present in many more men with castration-
sensitive metastatic PCa than previously expected, with 11.8% of
such patients having germline DRG mutations. It is inevitable, and
therefore that consideration will be given to screening these men.
Thirdly, it is also now apparent that DRG mutations are more
common in men with aggressive localized PCa than previously
reported and that the presence of DRG mutations is predictive of
death from PCa. Fourth, DRG mutations are a highly promising
target for therapeutic options such as PARP inhibition and plat-
inum, and perhaps as a neoadjuvant or adjuvant strategy for
localized PCa3,4.
In terms of practice, this means that biopsies will be performed
more often to assess heterogeneity, including liquid biopsies. Ge-
nomics will also be more commonly used.
In conclusion, AR-targeted agents are very effective in mCRPC.
Costs and access remain an issue, especially in the Asia-Pacific re-
gion. Biomarkers and patient selection will become more sophis-
ticated, and a precision approach should help to increase value in
the future. Efforts such as A-CaP will create opportunities to assess
patterns of care and conduct research. It is important to approach
big pharma for support for such initiatives.3.3.1. Discussion
Hideyuki Akaza noted that pharmaceutical companies generate
very large profits and asked about how to approach them. Declan
Murphy noted that many pharmaceutical companies are looking
for initiatives to support and that with Matthew Cooperberg's
opinions and expertise as well, it could be very possible to find
grant funding from pharmaceutical companies.4. Publication rules
In the business meeting held prior to the main symposium, A-
CaP members noted that following the collection of all A-CaP data,
a prime objective will be to report on the work of A-CaP through
scientific publications. Considering the multiinternational, multi-
center nature of the A-CaP group, the matter of authorship is an
important issue to consider ahead of proceeding with the project.
A proposal was made concerning the Principles of Authorship in
Collaborative Studies, which was adopted from the GAP3 Active
Surveillance Project Guidelines. It was noted that all members
would be forwarded details of these principles for future refer-
ence. It was further noted that if A-CaP members have ideas for
articles based on A-CaP data and discussions, they are requested
to provide their opinions to the A-CaP office. The A-CaP office will
look into publishing a preliminary overview of the data accumu-
lated to date.Conflicts of interest
No conflicts of interest for all authors.Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.prnil.2018.06.001.
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